

## DAFTAR PUSTAKA

1. PDPI. *Pneumonia Covid-19 Diagnosis dan Penatalaksanaan di Indonesia*. Jakarta: Perhimpunan Dokter Paru Indonesia; 2020. 1-49
2. Gallelli L, Zhang L, Wang T, Fu F. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin. *J Clin Pharmacol*. 2020;60(7):815–25.
3. Magro G. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? *SGP130Fc*. 2020;2(2):100029: 1-6
4. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. *Cytokine Growth Factor Rev*. 2020;54(January):62–75.
5. Gubernatorova EO, Gorshkova EA, Polinova AI, Drutskaya MS. IL-6: Relevance for Immunopathology of SARS-CoV-2. Russia: Elsevier; 2020; 53 : 13-20.
6. Ali MJ, Hanif M, Haider MA, Ahmed MU, Sundas FNU, Hirani A, et al. Treatment Options for COVID-19: A Review. *Front Med*. 2020;7(7):1–10.
7. Caramori G, Mumby S, Girbino G, Chung KF, Adcock IM. *Corticosteroids*. Italy: Springer International Publishing; 2019 : 661-84
8. Yasir M, Sonthalia S. Corticosteroid Adverse Effects. *StatPearls [Internet]*. 2019; 1-20
9. Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, Susilo A, et al. *Pedoman Tatalaksana Covid-19 Edisi 3*. Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi. 2020. 3–6, 88–9.
10. Awasthi S, Wagner T, Venkatakrisnan AJ, Puranik A, Hurchik M, Agarwal V, et al. Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients. *Cell Death Discov*. 2021;7(1).1-9.
11. Santa Cruz A, Mendes-Frias A, Oliveira AI, Dias L, Matos AR, Carvalho A, et al. Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. *Front Immunol*. 2021;12(2):1–10.
12. Gorham J, Moreau A, Corazza F, Peluso L, Ponthieux F, Talamonti M, et al. Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis. *PLoS One*. 2020;15(12 12):1–11.
13. WHO. *Coronavirus Disease (Covid-19)*. US: World Health Organization; 2020.1-10.
14. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol [Internet]*. 2021;19(3):141–54.

15. Dhar Chowdhury S, Oommen AM. Epidemiology of COVID-19. *J Dig Endosc.* 2020;11(01):03–7.
16. Rauf A, Abu-izneid T, Olatunde A, Khalil AA, Alhumaydhi FA, Tufail T, et al. COVID-19 Pandemic : Epidemiology , Etiology , Conventional and Non-Conventional Therapies. *Int J Environ Res Public Health.* 2020 Nov 4;17(21):8155: 1-24.
17. Hikmawati I, Setiyabudi R. Epidemiology of COVID-19 in Indonesia: common source and propagated source as a cause for outbreaks. *J Infect Dev Ctries.* 2021;15(5):646–52.
18. Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Sinto R, et al. Coronavirus Disease 2019 : Tinjauan Literatur Terkini Coronavirus Disease 2019 : Review of Current Literatures. *J Penyakit Dalam Indones.* 2020;7(1):45–67.
19. Rothan HA, Byrareddy SN. The epidemiology and Pathogenesis of Coronavirus Disease (Covid-19) Outbreak. USA: Elsevier; 2020;(January):5411–3.
20. Santos I de A, Grosche VR, Bergamini FRG, Sabino-Silva R, Jardim ACG. Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment? *Front Microbiol.* 2020;11(8).75-83
21. Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, et al. Cell entry mechanisms of SARS-CoV-2. *Proc Natl Acad Sci U S A.* 2020;117(21). 11727-34.
22. Su H, Xu Y, Jiang H. Drug discovery and development targeting the life cycle of SARS-CoV-2. *Fundam Res.* 2021;1(2):151–65.
23. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. *Front Immunol.* 2020;11(July):1–13
24. Copaescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. *J Allergy Clin Immunol.* 2020;146(3):518-34.
25. Krishnan A, Hamilton JP, Alqahtani SA, Woreta TA. COVID-19: An overview and a clinical update. *World J Clin Cases.* 2021;9(1):8–23.
26. Velazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez LL, Borca M V. The role of interleukin 6 during viral infections. *Front Microbiol.* 2019;10(5):6–11.
27. Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. *Cytokine.* 2014;70(1):11–20.
28. Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. *Rev Med Virol.* 2020;30(6):1–9.
29. Sabaka P, Koščálová A, Straka I, Hodosy J, Lipták R, Kmotorková B, et al. Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during

- Covid-19 outbreak. *BMC Infect Dis.* 2021;21(1):4–11.
30. Sun H, Guo P, Zhang L, Wang F. Serum interleukin-6 concentrations and the severity of COVID-19 pneumonia: A retrospective study at a single center in Bengbu City, Anhui Province, China, in January and February 2020. *Med Sci Monit.* 2020;26:1–6.
  31. Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Confronting the controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome. *Eur Respir J.* 2020;56(4). 21-52
  32. Hodgens A, Sharman T. *Corticosteroids.* Treasure Island: Statpearls Publishing; 2021. 1-12
  33. Williams DM. Clinical pharmacology of corticosteroids. *Respir Care.* 2018;63(6):655–70.
  34. Raju R, V. P, Biatrix PS, J. SJUC. Therapeutic role of corticosteroids in COVID-19: a systematic review of registered clinical trials. *Futur J Pharm Sci.* 2021;7(1). 23-45.
  35. Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. *Signal Transduct Target Ther.* 2020;5(1):17–9.
  36. Ni YN, Chen G, Sun J, Liang BM, Liang ZA. The effect of corticosteroids on mortality of patients with influenza pneumonia: A systematic review and meta-analysis. *Crit Care.* 2019;23(1):1–9.
  37. Langarizadeh MA, Tavakoli MR, Abiri A, Ghasempour A, Rezaei M, Ameri A. A review on function and side effects of systemic corticosteroids used in high-grade covid-19 to prevent cytokine storms. *EXCLI J.* 2021;20:339–65.
  38. Li X, Fu Z, Liang H, Wang Y, Qi X, Ding M, et al. H5N1 influenza virus-specific miRNA-like small RNA increases cytokine production and mouse mortality via targeting poly(rC)-binding protein 2. *Cell Res.* 2018;28(2):157–71.
  39. Maucourant C, Queiroz GAN, Samri A, Grassi MFR, Yssel H, Vieillard V. Zika virus in the eye of the cytokine storm. *Eur Cytokine Netw.* 2019;30(3):74–81.
  40. Yang CL, Qiu X, Zeng YK, Jiang M, Fan HR, Zhang ZM. Coronavirus disease 2019: A clinical review. *Eur Rev Med Pharmacol Sci.* 2020;24(8):4585–96.
  41. Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, et al. Use of convalescent plasma therapy in two covid-19 patients with acute respiratory distress syndrome in Korea. *J Korean Med Sci.* 2020;35(14):2–9.
  42. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. *Clin Immunol.* 2020 May;214:108393.1-5.



43. Siddiqi H, Mehra M. COVID-19 illness in native and immunosuppressed states: *Ann Oncol*. 2020;(1):19–21.
44. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. *Lancet*. 2020;395(1):683–4.
45. Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. *Life Sci*. 2020 Jul 15;253:117592. 1-5.
46. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. *Virol Sin*. 2020;35(3):266–71.
47. Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(1):497–506.
48. Nilea SH, Nilea A, Qiu J, Lib L, Jiac X, Kaia G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. *Cytokine Growth Factor Rev*. 2020;54(1):66–70.
49. Ehrchen JM, Roth J, Barczyk-Kahlert K. More than suppression: Glucocorticoid action on monocytes and macrophages. *Front Immunol*. 2019;10(8). 1-12.
50. Awasthi S, Wagner T, Venkatakrisnan AJ, Puranik A, Hurchik M, Agarwal V, et al. Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients. *Cell Death Discov*. 2021;7(1). 1-15.
51. Liu F, Ji C, Luo J, Wu W, Zhang J, Zhong Z, et al. Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019. *Sci Rep*. 2020;10(1):1–9.
52. Wang J, Yang W, Chen P, Guo J, Liu R, Wen P, et al. The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis. *PLoS One*. 2021;16(4):1–23.
53. Gager GM, Biesinger B, Hofer F, Winter MP, Hengstenberg C, Gilma B, et al. Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome. *Vascul Pharmacol [Internet]*. 2020;135(9):1-9.
54. Su JH, Luo MY, Liang N, Gong SX, Chen W, Huang WQ, et al. Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases. *Front Pharmacol*. 2021;12(8):1–13.
55. Tanase DM, Gosav EM, Radu S, Ouatu A, Rezus C, Ciocoiu M, et al. Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker? *Int J Hypertens*. 2019;2019. 1-12.
56. Bordallo B, Bellas M, Cortez AF, Vieira M, Pinheiro M. Severe COVID-19: what have we learned with the immunopathogenesis? *Adv Rheumatol (London, England)*. 2020 Sep;60(1):50-62.

57. Sindhu S, Thomas R, Shihab P, Sriraman D, Behbehani K, Ahmad R. Obesity is a positive modulator of IL-6R and IL-6 expression in the subcutaneous adipose tissue: Significance for metabolic inflammation. *PLoS One*. 2015;10(7):1–17.
58. Matuschik L, Riabov V, Schmuttermaier C, Sevastyanova T, Weiss C, Klüter H, et al. Hyperglycemia Induces Inflammatory Response of Human Macrophages to CD163-Mediated Scavenging of Hemoglobin-Haptoglobin Complexes. *Int J Mol Sci*. 2022;23(3):1–19.
59. Sun Q, Li J, Gao F. New insights into insulin: The anti-inflammatory effect and its clinical relevance. *World J Diabetes*. 2014;5(2):89-96.
60. Gao Y dong, Ding M, Dong X, Zhang J jin, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. *Allergy Eur J Allergy Clin Immunol*. 2021;76(2):428–55.
61. Surendra H, Elyazar IR, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. *Lancet Reg Heal - West Pacific*. 2021;9:100-8.
62. Jouan Y, Guillon A, Leclerc M, Coffre C, Bourgoin H. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 A Randomized Clinical Trial. 2020;1298–306.
63. Dahlan MS. Statistik untuk Kedokteran dan Kesehatan (Deskriptif, Bivariat, dan Multivariat Dilengkapi Analisis dengan Menggunakan SPSS. 3rd ed. Jakarta: Salemba Medika; 2016. 17-23.
64. Al-Mudhaffer RH, Ahjel SW, Hassan SM, Mahmood AA, Hadi NR. Age Distribution of Clinical Symptoms, Isolation, Co-morbidities and Case Fatality Rate of COVID-19 Cases in Najaf City, Iraq. *Med Arch (Sarajevo, Bosnia Herzegovina)*. 2020;74(5):363–7.
65. Taberner E, Ruiz LA, España PP, Méndez R, Serrano L, Santos B, et al. COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences. Vol. 50, *Infection*. 2022. p. 179–89.
66. Gómez-Belda AB, Fernández-Garcés M, Mateo-Sanchis E, Madrazo M, Carmona M, Piles-Roger L, et al. COVID-19 in older adults: What are the differences with younger patients? *Geriatr Gerontol Int*. 2021;21(1):60–5.
67. Fabio P, Graziamaria C. COVID- 19 and the elderly insights into pathogenesis.pdf. Vol. 32, *Aging Clinical and Experimental Research*. 2020. p. 1599–608.
68. Liu Y, Mao B, Liang S, Yang JW, Lu HW, Chai YH, et al. Association between age and clinical characteristics and outcomes of COVID-19. *Eur Respir J*. 2020;318(6). 1-4.
69. Fortunato F, Martinelli D, Lo Caputo S, Santantonio T, Dattoli V, Lopalco PL, et al. Sex and gender differences in COVID-19: An Italian local register-based study. *BMJ Open*. 2021;11(10):1–7.

70. Falchi A, Fernández-De-Las-Peñas C, Martín-Guerrero JD, Pellicer-Valero ÓJ, Navarro-Pardo E, Gómez-Mayordomo V, et al. 2022, 11, 413. *J Clin Med*. 2022;2022:413-24.
71. Doerre A, Doblhammer G. The influence of gender on COVID-19 infections and mortality in Germany: Insights from age- and gender-specific modeling of contact rates, infections, and deaths in the early phase of the pandemic. *PLoS One*. 2022;17(5):1–20.
72. Raimondi F, Novelli L, Ghirardi A, Russo FM, Pellegrini D, Biza R, et al. Covid-19 and gender: lower rate but same mortality of severe disease in women—an observational study. *BMC Pulm Med*. 2021;21(1):1–11.
73. Gagliardi MC, Tieri P, Ortona E, Ruggieri A. ACE2 expression and sex disparity in COVID-19. *Cell Death Discov*. 2020;6(1):1–2.
74. Kidron R, Robinson S. The importance of computerized tomography in psychiatry. *Isr J Psychiatry Relat Sci*. 1982;19(2):165–72.
75. Gong J, Dong H, Xia QS, Huang Z yi, Wang D kun, Zhao Y, et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study. *BMC Infect Dis*. 2020;20(1):1–7.
76. Granholm A, Kjær MBN, Munch MW, Myatra SN, Vijayaraghavan BKT, Cronhjort M, et al. Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia. *Intensive Care Med*. 2022;48(5):580–9.
77. FakhriRavari A, Jin S, Kachouei FH, Le D, Lopez M. Systemic corticosteroids for management of COVID-19: Saving lives or causing harm? *Int J Immunopathol Pharmacol*. 2021;35:1–14.
78. Dwi Ananda RY, Nova Kurniati, Harun Hudari, Erial Bahar. Correlation of Interleukin-6 Levels with Clinical Features and Chest X-Ray Imaging in Coronavirus Disease-19 (COVID-19) Patients at Dr. Mohammad Hoesin General Hospital Palembang. *Biosci Med J Biomed Transl Res*. 2022;6(5):1799–805.
79. Mojtabavi H, Saghazadeh A, Rezaei N. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis. *Eur Cytokine Netw*. 2020;31(2):44–9.
80. Xiang Z, Liu J, Shi D, Chen W, Li J, Yan R, et al. Glucocorticoids improve severe or critical covid-19 by activating ace2 and reducing il-6 levels. *Int J Biol Sci*. 2020;16(13):2382–91.
81. Del Valle DM, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts {COVID}-19 severity and survival. *Nat Med*. 2020;26(10):1636–43.
82. Namazi N. The effectiveness of dexamethasone as a combination therapy for COVID-19. *Acta Pharm*. 2022;72(3):345–58.
83. Xiong B, Du H, Zhan Z, Zhang A, He LM, Qin YY, et al. Effectiveness of adjunctive corticosteroid therapy in patients with severe COVID-19: A



- retrospective cohort study. *World J Clin Cases*. 2021;9(15):3546–58.
84. Fujino M, Ishii M, Taniguchi T, Chiba H, Kimata M, Hitosugi M. The value of interleukin-6 among several inflammatory markers as a predictor of respiratory failure in COVID-19 patients. *Diagnostics*. 2021;11(8). 1-4.
  85. King EM, Chivers JE, Rider CF, Minnich A, Gienbycz MA, Newton R. Glucocorticoid Repression of Inflammatory Gene Expression Shows Differential Responsiveness by Transactivation- and Transrepression- Dependent Mechanisms. *PLoS One*. 2013;8(1). 1-4.
  86. Chen H, Xie J, Su N, Wang J, Sun Q, Li S, et al. Corticosteroid Therapy Is Associated With Improved Outcome in Critically Ill Patients With COVID-19 With Hyperinflammatory Phenotype. *Chest*. 2021;159(5):1793–802.
  87. Sanyaolu A, Okorie C, Marinkovic A, Patidar R. Comorbilidad y su impacto en pacientes con COVID-19. *SN Compr Clin Med*. 2020;2:1069–76.
  88. Luporini RL, Rodolpho JM, Kubota LT. IL\_6 and IL\_10 are associated with disease severity and higher comorbidity in adults with COVID-19. *Elsevier*. 2021;1(4):1-3.
  89. Barh D, Aljabali AA, Tambuwala MM, Tiwari S, Serrano-Aroca Á, Alzahrani KJ, et al. Predicting COVID-19—comorbidity pathway crosstalk-based targets and drugs: Towards personalized COVID-19 management. *Biomedicines*. 2021;9(5):1–16.
  90. Zúñiga MÁL, Moreno-Moral A, Ocaña-Granados A, Padilla-Moreno FA, Castillo-Fernández AM, Guillamón-Fernández D, et al. High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response. *PLoS One*. 2021;16(1):1–13.
  91. Munch MW, Myatra SN, Vijayaraghavan BKT, Saseedharan S, Benfield T, Wahlin RR, et al. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive without Life Support in Adults with COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. *JAMA - J Am Med Assoc*. 2021;326(18):1807–17.